pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

DECEMBER 21, 2020

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2

Immune Response 59

Immune Response Sales Antibody Drugs 59

pharmaphorum

JANUARY 7, 2021

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

Immune Response 53

Immune Response Doctors Doctor Pharma Companies 53

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

pharmaphorum

MAY 14, 2021

This and its smaller size – it’s a “nanobody” that is only a fraction of the size of conventional antibodies – could allow it to penetrate deeper into the skin and joints. Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential. is the future in inflammatory diseases.”.

Drugs 66

Drugs Licensing Licensing Development 66

Delveinsight

AUGUST 13, 2020

The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size. Takeda acquired an exclusive global license for CNP-101 from Cour Pharmaceuticals’in October 2019.

Marketing 52

Marketing Trials Antibody Pharma Companies 52

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. If the Australian pharma company can demonstrate a renewed potential for the drug, Lilly could receive up to $255m in commercial and regulatory milestone payments.

Development 130

Development Antibody Pharma Companies Licensing 130

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 81

Antibody Licensing Licensing Protein 81

Delveinsight

AUGUST 2, 2020

Helsinn Group , a Swiss pharma player, is evaluating Anamorelin, an orally active selective ghrelin receptor agonist against Cancer cachexia, The company is conducting Phase III trial to test the efficacy and safety of anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

SEPTEMBER 8, 2022

It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Big pharma has already noted its interest in the area, as seen in Novartis’ investments. The reason for the shutdown was due to potential discovery of quality issues at its plants.

Manufacturing 105

Manufacturing Development Antibody Drugs 105

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

XTalks

MAY 29, 2024

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

Delveinsight

SEPTEMBER 7, 2021

California-based pharma company Forte has been testing FB-401 , which comprises three therapeutic strains of a commensal gram-negative bacteria, as a possible therapy for atopic dermatitis. Versanis Bio, an Oakland, Calif-based company has licensed Novartis’s Bimagrumab drug rights and raised $70 million for mid-stage clinical testing.

Vaccination 70

Vaccination Vaccine Antibody Trials 70

pharmaphorum

DECEMBER 21, 2020

The body produces antibodies against the protein, which neutralise the virus in the event of an infection. While Moderna blazed its investment trail and tried to find ways to make sure its mRNA vaccines did not produce dangerous immune reactions, a small biotech called BioNTech had licensed in the technology from Kariko and Weissman.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

DECEMBER 16, 2020

the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions.

Vaccination 52

Vaccination Vaccine DNA Antibody 52

Roots Analysis

JANUARY 27, 2025

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. Such deals are inked to allow companies to expand their respective technology / product portfolios, and gain additional capabilities related to subcutaneous biologics.

Marketing 40

Marketing Drug Delivery Development Protein 40